No Picture
News

Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline

SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) — Gyre Therapeutics, Inc. (Gyre or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, today […]

No Picture
News

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

NEW HAVEN, Conn. & SAN DIEGO–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB) (“Rallybio”) and Candid Therapeutics, Inc. (“Candid”), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager (“TCE”) therapeutics for autoimmune diseases, today announced […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant […]

No Picture
News

Airgain and Nextivity Enter Strategic Partnership on Co-developing Next Generation Integrated 4G / 5G Solutions

SAN DIEGO–(BUSINESS WIRE)—- $AIRG #5GCoverage–Airgain, Inc. (NASDAQ: AIRG), a leading provider of wireless connectivity solutions, and Nextivity, Inc., an industry leader in intelligent cellular coverage solutions, today announced they have entered into a Strategic Partnership […]


ADVERTISEMENT — Advertise With Biotech Networks
News

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

Spinoff from Novartis AG’s acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses from the Phase 3 OASIS-HAE […]

No Picture
News

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Arima Genomics Announces Publication of New Study Supporting the Whole-Genome Rearrangement Detection Approach Behind Aventa Lymphoma

CARLSBAD, Calif.–(BUSINESS WIRE)–Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the publication of a new research study from collaborators at the University of […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026

SAN JOSE, Calif.–(BUSINESS WIRE)– #NGS–Takara Bio USA collaborates with Illumina on a single-cell-resolution spatial mapping workflow, presented at AGBT 2026. Click here to view original post Click Here to Publish/Feature Your Company or Product News […]

No Picture
News

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced that it will report […]

No Picture
News

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for olezarsen for severe hypertriglyceridemia (sHTG). The […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview

SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2025. “Acadia closed 2025 with another strong quarter, capping a milestone year in […]

News

Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics

At AGBT, researchers reveal new findings from studies leveraging Illumina’s multiomics solutions SAN DIEGO, Feb. 25, 2026 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina’s spatial transcriptomics, […]


ADVERTISEMENT — Advertise With Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced […]

No Picture
News

Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq: GOSS) a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

biomodal and Element Biosciences Combine Duet Multiomic and High-Throughput Sequencing Capabilities to Advance Clinical Research

CAMBRIDGE, England & SAN DIEGO–(BUSINESS WIRE)–biomodal, an omics-based life sciences technology and analytics company, today announced at the AGBT 2026 General Meeting that biomodal’s duet multiomic solutions are compatible with Element Biosciences AVITI24™ 5D multiomics […]

News

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

SAN DIEGO, Feb. 23, 2026 /PRNewswire/ — Avidity Biosciences, Inc. (“Avidity”) (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (“AOCs™”) to profoundly improve people’s lives, […]